New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022.
cardiovascular
cardiovascular pharmacological strategies
drug combinations
drugs
pharmacological agents
Journal
European heart journal. Cardiovascular pharmacotherapy
ISSN: 2055-6845
Titre abrégé: Eur Heart J Cardiovasc Pharmacother
Pays: England
ID NLM: 101669491
Informations de publication
Date de publication:
11 May 2023
11 May 2023
Historique:
pmc-release:
11
05
2024
medline:
12
5
2023
pubmed:
12
5
2023
entrez:
11
5
2023
Statut:
aheadofprint
Résumé
Cardiovascular diseases (CVD) remain the leading cause of death worldwide and pharmacotherapy of most of them is suboptimal. Thus, there is a clear unmet clinical need to develop new pharmacological strategies with greater efficacy and better safety profiles. In this review, we summarize the most relevant advances in cardiovascular pharmacology in 2022 including the approval of first-in-class drugs that open new avenues for the treatment of obstructive hypertrophic cardiomyopathy (mavacamten), type 2 diabetes mellitus (tirzepatide), and heart failure (HF) independent of left ventricular ejection fraction (sodium-glucose cotransporter 2 inhibitors). We also dealt with fixed dose combination therapies repurposing different formulations of "old" drugs with well-known efficacy and safety for the treatment of patients with acute decompensated HF (acetazolamide plus loop diuretics), atherosclerotic cardiovascular disease (moderate-dose statin plus ezetimibe), Marfan syndrome (angiotensin receptor blockers plus β-blockers), and secondary cardiovascular prevention (i.e. low-dose aspirin, ramipril and atorvastatin), thereby filling existing gaps in knowledge, and opening new avenues for the treatment of CVD. Clinical trials confirming the role of dapagliflozin in patients with HF and mildly reduced or preserved ejection fraction, long-term evolocumab to reduce the risk of cardiovascular events, vitamin K antagonists for stroke prevention in patients with rheumatic heart disease-associated atrial fibrillation, antibiotic prophylaxis in patients at high risk for infective endocarditis before invasive dental procedures, and vutrisiran for the treatment of hereditary transthyretin-related amyloidosis with polyneuropathy were also reviewed. Finally, we briefly discuss recent clinical trials suggesting that FXIa inhibitors may have the potential to uncouple thrombosis from hemostasis and attenuate/prevent thromboembolic events with minimal disruption of hemostasis.
Identifiants
pubmed: 37169875
pii: 7160449
doi: 10.1093/ehjcvp/pvad034
pmc: PMC10236523
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL160992
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
Circ Res. 2019 Jan 18;124(2):328-350
pubmed: 30653440
Lancet Diabetes Endocrinol. 2022 Jun;10(6):393-406
pubmed: 35468325
Drugs. 2022 Jul;82(10):1127-1135
pubmed: 35802255
Cardiovasc Diabetol. 2022 Sep 1;21(1):169
pubmed: 36050763
Biophys Rev. 2018 Feb;10(1):27-48
pubmed: 28717924
Eur Heart J. 2015 Nov 21;36(44):3075-3128
pubmed: 26320109
Lancet. 2021 Sep 25;398(10306):1133-1146
pubmed: 34469765
Lancet. 2010 Nov 13;376(9753):1670-81
pubmed: 21067804
Eur Heart J. 2023 Jan 21;44(4):280-292
pubmed: 36263776
Drugs. 2022 Sep;82(13):1419-1425
pubmed: 35997942
Eur J Heart Fail. 2019 Nov;21(11):1415-1422
pubmed: 31074184
N Engl J Med. 2022 Sep 15;387(11):967-977
pubmed: 36018037
Mol Metab. 2018 Dec;18:3-14
pubmed: 30473097
Circ Res. 2017 Sep 15;121(7):749-770
pubmed: 28912181
Am J Cardiol. 2018 Oct 1;122(7):1231-1235
pubmed: 30149886
J Thromb Haemost. 2015 Aug;13(8):1383-95
pubmed: 25976012
N Engl J Med. 2000 Mar 9;342(10):696-701
pubmed: 10706899
Nat Med. 2022 Mar;28(3):591-598
pubmed: 35210595
Nat Rev Neurol. 2019 Jul;15(7):387-404
pubmed: 31209302
J Am Coll Cardiol. 2016 Aug 23;68(8):789-801
pubmed: 27539170
Amyloid. 2023 Mar;30(1):1-9
pubmed: 35875890
Diabetes Care. 2020 Jun;43(6):1352-1355
pubmed: 32291277
Heart Fail Rev. 2015 Mar;20(2):163-78
pubmed: 25408161
Cold Spring Harb Perspect Biol. 2018 Feb 1;10(2):
pubmed: 29419405
Eur Heart J. 2022 Feb 03;43(5):416-426
pubmed: 34878502
Atherosclerosis. 2014 Dec;237(2):829-37
pubmed: 25463129
N Engl J Med. 2022 Sep 15;387(11):978-988
pubmed: 36036525
JAMA Cardiol. 2022 Dec 1;7(12):1259-1263
pubmed: 36190011
Pflugers Arch. 2019 May;471(5):701-717
pubmed: 30767072
Lancet. 2022 Jul 30;400(10349):380-390
pubmed: 35863366
Acta Cardiol. 2015 Jun;70(3):265-73
pubmed: 26226699
N Engl J Med. 2011 Mar 3;364(9):797-805
pubmed: 21366472
Lancet Diabetes Endocrinol. 2022 Dec;10(12):869-881
pubmed: 36372069
Circulation. 2022 Oct 11;146(15):1109-1119
pubmed: 36031810
Science. 2016 Feb 5;351(6273):617-21
pubmed: 26912705
J Am Coll Cardiol. 2022 May 3;79(17):e263-e421
pubmed: 35379503
Diabetes Obes Metab. 2021 Sep;23 Suppl 3:5-29
pubmed: 34310013
J Biol Chem. 2017 Oct 6;292(40):16571-16577
pubmed: 28808052
Int J Cardiol Heart Vasc. 2018 Mar 12;18:71-80
pubmed: 29876507
Cardiovasc Res. 2020 Jul 15;116(9):1585-1599
pubmed: 32365196
Am J Cardiol. 2010 Jan 4;105(1 Suppl):21A-9A
pubmed: 20102970
Sci Rep. 2021 Oct 27;11(1):21179
pubmed: 34707178
J Am Soc Nephrol. 2016 Dec;27(12):3706-3714
pubmed: 27153921
J Am Coll Cardiol. 2022 Sep 13;80(11):1029-1041
pubmed: 35987887
N Engl J Med. 2022 Sep 29;387(13):1185-1195
pubmed: 36027559
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
Curr Probl Cardiol. 2023 Jan;48(1):101429
pubmed: 36167226
J Am Coll Cardiol. 2022 Jul 12;80(2):95-108
pubmed: 35798455
Can J Cardiol. 2014 May;30(5):520-6
pubmed: 24786442
BMJ. 2003 Jun 28;326(7404):1419
pubmed: 12829553
Lancet. 2022 Sep 10;400(10355):822-831
pubmed: 36049495
Blood. 2017 Mar 2;129(9):1210-1215
pubmed: 28039189
J Am Coll Cardiol. 2021 Aug 10;78(6):625-631
pubmed: 34353538
Circ Res. 2017 Jan 6;120(1):229-243
pubmed: 28057795
Am Heart J. 1955 Apr;49(4):626-32
pubmed: 14349876
Int J Cardiol. 2015 Dec;201 Suppl 1:S15-22
pubmed: 26747390
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
Expert Opin Investig Drugs. 2022 Oct;31(10):1027-1052
pubmed: 36062808
J Am Coll Cardiol. 2022 Feb 1;79(4):390-414
pubmed: 35086661
Am J Hypertens. 2006 Mar;19(3):282-5
pubmed: 16500514
Int J Cardiol. 2022 Aug 15;361:116-123
pubmed: 35569611
J Am Coll Cardiol. 2020 Dec 22;76(25):3022-3055
pubmed: 33229115
Blood Rev. 2018 Nov;32(6):433-448
pubmed: 30075986
Circulation. 2019 Jul 2;140(1):16-26
pubmed: 31109193
N Engl J Med. 2022 Sep 22;387(12):1089-1098
pubmed: 36027570
Cell Physiol Biochem. 2013;32(5):1151-66
pubmed: 24335166
Circ Heart Fail. 2009 Jan;2(1):56-62
pubmed: 19750134
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Clin Drug Investig. 2017 Dec;37(12):1175-1181
pubmed: 28965280
J Neurol. 2021 Jun;268(6):2109-2122
pubmed: 31907599
Am J Physiol Heart Circ Physiol. 2020 Mar 1;318(3):H715-H722
pubmed: 32083971
J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209
pubmed: 30423391
JACC Heart Fail. 2018 Apr;6(4):273-285
pubmed: 29226815
N Engl J Med. 2021 Jan 21;384(3):216-228
pubmed: 33186492
Ann Intern Med. 2014 Apr 1;160(7):468-76
pubmed: 24514899
Proc Natl Acad Sci U S A. 2022 Mar 29;119(13):e2116506119
pubmed: 35333651